JP7728704B2 - 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用 - Google Patents

炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用

Info

Publication number
JP7728704B2
JP7728704B2 JP2021552816A JP2021552816A JP7728704B2 JP 7728704 B2 JP7728704 B2 JP 7728704B2 JP 2021552816 A JP2021552816 A JP 2021552816A JP 2021552816 A JP2021552816 A JP 2021552816A JP 7728704 B2 JP7728704 B2 JP 7728704B2
Authority
JP
Japan
Prior art keywords
oligomer
spacer
formula
mmol
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523570A (ja
JPWO2020182635A5 (enExample
Inventor
アダモ，ロベルト
ベルティ，フランチェスコ
コスタンティーノ，パオロ
ライ，ルイージ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2022523570A publication Critical patent/JP2022523570A/ja
Publication of JPWO2020182635A5 publication Critical patent/JPWO2020182635A5/ja
Priority to JP2025050172A priority Critical patent/JP2025111445A/ja
Application granted granted Critical
Publication of JP7728704B2 publication Critical patent/JP7728704B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552816A 2019-03-08 2020-03-06 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用 Active JP7728704B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050172A JP2025111445A (ja) 2019-03-08 2025-03-25 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19161716.6 2019-03-08
EP19161716 2019-03-08
PCT/EP2020/055950 WO2020182635A1 (en) 2019-03-08 2020-03-06 Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050172A Division JP2025111445A (ja) 2019-03-08 2025-03-25 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2022523570A JP2022523570A (ja) 2022-04-25
JPWO2020182635A5 JPWO2020182635A5 (enExample) 2023-02-28
JP7728704B2 true JP7728704B2 (ja) 2025-08-25

Family

ID=66000932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552816A Active JP7728704B2 (ja) 2019-03-08 2020-03-06 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用
JP2025050172A Pending JP2025111445A (ja) 2019-03-08 2025-03-25 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050172A Pending JP2025111445A (ja) 2019-03-08 2025-03-25 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用

Country Status (8)

Country Link
US (1) US20220152183A1 (enExample)
EP (1) EP3934696A1 (enExample)
JP (2) JP7728704B2 (enExample)
CN (1) CN114126662A (enExample)
BR (1) BR112021017239A2 (enExample)
CA (1) CA3131741A1 (enExample)
MX (1) MX2021010555A (enExample)
WO (1) WO2020182635A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0409750D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Integration of meningococcal conjugate vaccination
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
GB202013262D0 (en) * 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS Chemical Biology，2013年，Vol.8，pp.2561-2567，DOI: 10.1021/cb400463u
Carbohydrate Research，2018年，Vol.465，pp.44-51，DOI: 10.1016/j.carres.2018.06.007
Infection and Immunity，2002年，Vol.70，pp.3707-3713，DOI: 10.1128/IAI.70.7.3707-3713.2002

Also Published As

Publication number Publication date
WO2020182635A1 (en) 2020-09-17
CA3131741A1 (en) 2020-09-17
EP3934696A1 (en) 2022-01-12
JP2025111445A (ja) 2025-07-30
US20220152183A1 (en) 2022-05-19
JP2022523570A (ja) 2022-04-25
BR112021017239A2 (pt) 2021-11-09
CN114126662A (zh) 2022-03-01
MX2021010555A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
CA2961694C (en) Vaccines against streptococcus pneumoniae serotype 8
WO2019106201A1 (en) Vaccine against klebsiella pneumoniae
JP7680966B2 (ja) サポニン共役体及びそれを含むワクチン又は医薬組成物
US10087242B2 (en) Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X
JP2025111445A (ja) 炭素環誘導体及びそれらのコンジュゲート誘導体、並びにワクチンにおけるそれらの使用
EP3274358B1 (en) Vaccine against carbapenem-resistantklebsiella pneumoniae
JP6622804B2 (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン
WO2022106703A1 (en) Protected disaccharides, their process of preparation and their use in the synthesis of zwitterionic oligosaccharides, and conjugates thereof
JP2023538756A (ja) 合成ＭｅｎＡ抗原を含む髄膜炎菌に対する５価ワクチン
KR102803369B1 (ko) 클로스트리듐 디피실에 대한 안정성 백신
CN119095871A (zh) 预防/治疗铜绿假单胞菌感染
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8
HK1242329B (en) Vaccines against streptococcus pneumoniae serotype 8
HK1242329A1 (en) Vaccines against streptococcus pneumoniae serotype 8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250813

R150 Certificate of patent or registration of utility model

Ref document number: 7728704

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150